Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06384976 | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | PHASE2 | ACTIVE NOT_RECRUITING | 120 | — | — | Sep 20, 2024 | Jan 1, 2029 | Jan 13, 2025 | 1 | United States |
Confirmed disability Progression on the EDSS scale. The EDSS scale ranges from 0 to 10 in 0.5- unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist.
| Arm | Type | Description |
|---|---|---|
| KYV-101 CAR-T cells with lymphodepletion conditioning | EXPERIMENTAL | Dosing with KYV-101 CAR T cells |
| Anti- CD20 mAb | ACTIVE_COMPARATOR | Dosing with anti-CD20 mAb |
| Name | Type | Description |
|---|---|---|
| KYV-101 | BIOLOGICAL | Anti-CD19 CAR-T cell therapy |
| Standard lymphodepletion regimen | DRUG | CYC/FLU |
| Anti-CD20 mAB | DRUG | Anti-CD20 mAB |
Key Inclusion Criteria: 1. Subject must have a history of diagnosis of primary progressive or secondary progressive MS. 2. History of treatment with anti-CD20 mAb with continuing evidence of worsening physical disability over a period of ≥6 months, with documented clinical disability progression wi...